Skip to main content
OGN
NYSE Life Sciences

Organon Reports Mixed Q1 Results Amidst Pending Acquisition, Withdraws Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$13.29
Mkt Cap
$3.503B
52W Low
$5.69
52W High
$13.376
52W Position info
134% above low
Off High info
at 52W high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

OGN has more than doubled off its 52-week low of $5.69 on elevated volume (2.0× avg).

Summary

Organon reported a 4% revenue decline and 30% adjusted EPS drop for Q1 2026, but GAAP EPS increased, with no future guidance provided due to its pending acquisition by Sun Pharma.


Key Events · Earnings and Guidance · OGN

  • Q1 Revenue Decline

    Reported Q1 2026 revenue of $1.460 billion, a 4% decrease as-reported and 9% excluding foreign currency impact compared to Q1 2025.

  • Mixed Profitability

    GAAP diluted EPS increased 67% to $0.55, while non-GAAP Adjusted diluted EPS decreased 30% to $0.71. Adjusted EBITDA also declined 14%.

  • Biosimilars Segment Growth

    Biosimilars revenue increased 23% as-reported and 21% ex-FX, driven by strong performance of Hadlima and contributions from new assets.

  • Guidance Withdrawn Due to Merger

    In light of the pending merger with Sun Pharmaceutical Industries, Organon will not provide future financial guidance or host quarterly earnings calls.


Analysis · OGN · Life Sciences

Organon & Co. reported mixed financial results for the first quarter of 2026, with a 4% decline in as-reported revenue and a 30% drop in non-GAAP Adjusted diluted EPS. However, GAAP diluted EPS saw a significant 67% increase. The Biosimilars segment showed strong growth, up 23% as-reported, driven by Hadlima and new product contributions, which partially offset declines in Women's Health and Established Brands. The company has ceased providing financial guidance and will not host earnings calls due to its pending acquisition by Sun Pharmaceutical Industries, which was announced on April 26, 2026. This report provides a final detailed operational snapshot of the company's performance leading into the acquisition.

At the time of this filing, OGN was trading at $13.29 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $5.69 to $13.38. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OGN - Latest Insights

OGN
Jul 24, 2026, 1:42 AM EDT
Source: Moneycontrol
Importance Score:
8
Price at Filing: $13.56
Real-time Price: $13.52 info
Change: -$0.040 (-0.29%) info
Market Cap: $3.55B info
OGN
Jul 23, 2026, 5:13 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.56
Real-time Price: $13.52 info
Change: -$0.040 (-0.29%) info
Market Cap: $3.55B info
OGN
Jul 17, 2026, 4:12 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $13.52
Real-time Price: $13.52 info
Change: $0 (0%) info
Market Cap: $3.55B info
OGN
Jul 17, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $13.52
Real-time Price: $13.52 info
Change: $0 (0%) info
Market Cap: $3.55B info
OGN
Jul 17, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.52
Real-time Price: $13.52 info
Change: $0 (0%) info
Market Cap: $3.55B info